Share on LinkedInShare on LinkedIn

ARTICLE · 07 OCTOBER 2015

Claimed Formulation Not Obvious Despite Recitations Falling Within Prior Art Ranges

Addressing obviousness issues, the U.S. Court of Appeals for the Federal Circuit affirmed a lower court's finding that patents were valid and infringed, despite undeniably including recitations falling within a prior art range.

United StatesIntellectual Property

Allergan, Inc. v. Sandoz Inc.

Addressing obviousness issues, the U.S. Court of Appeals for the Federal Circuit affirmed a lower court's finding that patents were valid and infringed, despite undeniably including recitations falling within a prior art range. Allergan, Inc. v. Sandoz Inc., Case No. 14-1275 (Fed. Cir., Aug. 4, 2015) (Lourie, J.)

Allergan owns five patents related to Lumigan® 0.01% ("Lumigan 0.01%"), a glaucoma treatment product having 0.01% of bimatoprost and 200 ppm of benzalkonium chloride (BAK). Several companies filed Abbreviated New Drug Application (ANDA) applications for generic versions of Lumigan 0.01% (collectively ANDA applicants), causing Allergan to file a patent infringement lawsuit. After a bench trial, the district court held that Allergan's patents were not invalid for obviousness, lack of written description or lack of enablement and were infringed, entitling Allergan to a permanent injunction. The ANDA applicants appealed.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from